Prise en charge des cancers bronchiques non à petites cellules oligométastatiques

Dingemans, 2019, Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report, J Thorac Oncol, 14, 2109, 10.1016/j.jtho.2019.07.025

Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1

Lievens, 2020, Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document, Radither Oncol, 148, 157, 10.1016/j.radonc.2020.04.003

De Souza, 2018, Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 91, 153, 10.1016/j.ejca.2017.12.012

Downey, 2002, A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis, Lung Cancer, 38, 193, 10.1016/S0169-5002(02)00183-6

Collen, 2014, Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, 25, 1954, 10.1093/annonc/mdu370

De Ruysscher, 2018, Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450), J Thorac Oncol, 13, 1958, 10.1016/j.jtho.2018.07.098

Bergsma, 2017, Radiotherapy for Oligometastatic Lung Cancer, Front Oncol, 7, 210, 10.3389/fonc.2017.00210

Iyengar, 2018, Consolidative Radiotherapy for Limited Metastatic Non – Small-Cell Lung Cancer, JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501

Xu, 2018, Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchrnous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs, J Thorac Oncol, 13, 13831392

Jiang, 2019, EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases, Int J Cancer, 144, 2605, 10.1002/ijc.31962

Elamin, 2019, Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC), Clin Lung Cancer, 20, 43, 10.1016/j.cllc.2018.09.015

Hu, 2019, Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations, Clin Lung Cancer, 20, e81, 10.1016/j.cllc.2018.09.010

Ni, 2020, Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment, J Cancer Res Clin Oncol, 146, 197, 10.1007/s00432-019-03043-6

Wang, 2020, First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332), J Clin Oncol, 38

Bauml, 2019, Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial, JAMA Oncol, 5, 1283, 10.1001/jamaoncol.2019.1449

Palma, 2020, Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial, J Clin Oncol, JCO2000818

Ashworth, 2014, An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non – Small-Cell Lung Cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003

Guckenberger, 2016, Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy, Radiother Oncol, 118, 485, 10.1016/j.radonc.2015.09.008

de Baere, 2017, Lung ablation: Best practice/results/response assessment/role alongside other ablative therapies, Clin Radiol, 72, 657, 10.1016/j.crad.2017.01.005

de Baere, 2011, Radiofrequency ablation of liver and lung tumors, J Radiol, 92, 825, 10.1016/j.jradio.2011.07.005

Robin, 2018, A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management, Semin Radiat Oncol, 28, 288, 10.1016/j.semradonc.2018.06.009

Mazzella, 2019, Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer, Clin Lung Cancer, 20, 405, 10.1016/j.cllc.2019.06.003

Li, 2018, Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis, J Thorac Dis, 10, 3701, 10.21037/jtd.2018.05.105

Uppal, 2014, Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs, Clin Exp Metastasis, 31, 735, 10.1007/s10585-014-9664-3

Couñago, 2019, Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions, World J Clin Oncol., 10, 318, 10.5306/wjco.v10.i10.318

West, 2020, Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer, Clin Chest Med, 41, 249, 10.1016/j.ccm.2020.02.004